Overview

Patient Registry of Intrathecal Ziconotide Management(PRIZM)

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the effectiveness, long-term safety, tolerability, satisfaction with treatment, and health-related quality of life (HRQoL) associated with Intrathecal PRIALT use for severe chronic pain of varying etiologies.
Details
Lead Sponsor:
Jazz Pharmaceuticals
Treatments:
omega-Conotoxins
Ziconotide